Bob Soh, MD

Bob is an Investment Manager with Brandon Capital Partners, Australia's largest life sciences VC. Bob completed his MD in the University of Melbourne and undertook his surgical residency in Liverpool Hospital the Royal Melbourne Hospital. He subsequently ventured into the biotech sector, first as a clinical triallist with Nucleus Network, Australia’s largest clinical trials unit where he was an investigator in over 150 phase 1 to 2 trials; to running an early stage VC backed biotech company as the acting chief executive. He subsequently joined Brandon Capital in 2016, and is currently a director of Glyscend, and a board observer of EBR Systems.